Table A4Summary of the Incidence of Nonneoplastic Lesions in Male Tg.AC Hemizygous Mice in the 6-Month Dermal Study of Pentaerythritol Triacrylatea

Vehicle Control0.75 mg/kg1.5 mg/kg3 mg/kg6 mg/kg12 mg/kg
Disposition Summary
Animals initially in study151515151515
Early deaths
 Moribund11
 Natural deaths325
Survivors
 Terminal sacrifice121415151210
Animals examined microscopically151515151515
Alimentary System
Liver(15)(15)(15)(15)(15)(15)
 Atrophy1 (7%)
 Hematopoietic cell proliferation2 (13%)
 Infiltration cellular5 (33%)3 (20%)
 Inflammation, chronic active5 (33%)11 (73%)10 (67%)13 (87%)13 (87%)5 (33%)
 Mineralization1 (7%)
 Myelodysplasia5 (33%)
 Pigmentation1 (7%)1 (7%)
 Hepatocyte, necrosis1 (7%)1 (7%)1 (7%)1 (7%)
 Hepatocyte, vacuolization cytoplasmic1 (7%)
Salivary glands(1)(1)(1)(2)
 Parotid gland, infiltration cellular1 (50%)
Stomach, forestomach(15)(15)(15)(15)(15)(15)
 Hyperkeratosis2 (13%)1 (7%)3 (20%)4 (27%)
 Epithelium, hyperplasia1 (7%)
Cardiovascular System
Heart(15)(15)(15)(15)(15)(15)
 Infiltration cellular3 (20%)
 Inflammation, chronic active3 (20%)1 (7%)
 Myelodysplasia3 (20%)
Endocrine System
Adrenal cortex(15)(15)(15)(15)(15)(15)
 Hypertrophy7 (47%)10 (67%)3 (20%)5 (33%)1 (7%)3 (20%)
 Myelodysplasia2 (13%)
Adrenal medulla(15)(15)(15)(15)(15)(15)
 Infiltration cellular2 (13%)
 Myelodysplasia2 (13%)
Pituitary gland(15)(14)(15)(15)(15)(15)
 Pars distalis, cyst1 (7%)3 (20%)
Thyroid gland(15)(15)(15)(15)(15)(15)
 Inflammation, chronic active1 (7%)
 Myelodysplasia1 (7%)
General Body System
None
Genital System
Epididymis(15)(14)(15)(15)(15)(15)
 Infiltration cellular5 (33%)5 (33%)
 Inflammation, chronic active1 (7%)4 (27%)
 Myelodysplasia5 (33%)
 Bilateral, hypospermia1 (7%)
 Unilateral, hypospermia1 (7%)1 (7%)2 (13%)
Preputial gland(1)
 Duct, ectasia1 (100%)
Testes(15)(15)(15)(15)(15)(15)
 Cyst2 (13%)1 (7%)1 (7%)1 (7%)
 Bilateral, germinal epithelium, degeneration1 (7%)
 Unilateral, germinal epithelium, degeneration1 (7%)1 (7%)2 (13%)1 (7%)4 (27%)
Hematopoietic System
Bone marrow(1)
 Myeloid cell, hyperplasia1 (100%)
Lymph node(14)(15)(14)(13)(15)(14)
 Hyperplasia1 (7%)
 Infiltration cellular, plasma cell1 (7%)
 Inflammation, chronic active1 (7%)
 Myelodysplasia1 (7%)
 Axillary, hyperplasia, lymphoid1 (7%)
 Axillary, infiltration cellular1 (7%)1 (7%)
 Axillary, infiltration cellular, plasma cell1 (7%)1 (7%)
 Axillary, infiltration cellular, histiocyte1 (7%)
 Inguinal, myelodysplasia1 (7%)
 Mediastinal, hyperplasia1 (7%)
 Mediastinal, infiltration cellular4 (27%)2 (14%)
 Mediastinal, myelodysplasia1 (7%)
Lymph node, mandibular(15)(15)(15)(15)(15)(15)
 Hematopoietic cell proliferation3 (20%)
 Hyperplasia2 (13%)1 (7%)2 (13%)
 Hyperplasia, plasma cell1 (7%)
 Infiltration cellular5 (33%)6 (40%)
 Infiltration cellular, plasma cell1 (7%)6 (40%)
 Myelodysplasia2 (13%)
 Necrosis, lymphoid2 (13%)
Lymph node, mesenteric(12)(15)(15)(15)(15)(14)
 Hematopoietic cell proliferation1 (7%)1 (7%)
 Infiltration cellular4 (27%)2 (14%)
 Myelodysplasia3 (21%)
 Necrosis, lymphoid1 (7%)
Spleen(15)(15)(15)(15)(15)(15)
 Atrophy1 (7%)
 Depletion cellular2 (13%)2 (13%)
 Hematopoietic cell proliferation1 (7%)2 (13%)1 (7%)2 (13%)9 (60%)8 (53%)
 Infiltration cellular1 (7%)4 (27%)
 Myelodysplasia4 (27%)
 Necrosis, lymphoid2 (13%)1 (7%)
Thymus(15)(15)(15)(15)(14)(14)
 Atrophy4 (27%)1 (7%)2 (13%)4 (29%)5 (36%)
 Myelodysplasia3 (21%)
 Thymocyte, necrosis2 (14%)
Integumentary System
Skin(15)(15)(15)(15)(15)(15)
 Dermis, site of application, necrosis1 (7%)
 Epidermis, site of application, hyperplasia3 (20%)8 (53%)10 (67%)14 (93%)
 Epidermis, site of application, ulcer1 (7%)
 Site of application, cyst epithelial inclusion1 (7%)
 Site of application, hyperkeratosis1 (7%)2 (13%)6 (40%)10 (67%)13 (87%)
 Site of application, inflammation, chronic active2 (13%)5 (33%)12 (80%)
Musculoskeletal System
None
Nervous System
None
Respiratory System
Lung(15)(15)(15)(15)(15)(15)
 Infiltration cellular1 (7%)3 (20%)
 Inflammation, chronic active1 (7%)2 (13%)
 Myelodysplasia3 (20%)
 Alveolar epithelium, hyperplasia1 (7%)
 Mediastinum, infiltration cellular1 (7%)
Special Senses System
None
Urinary System
Kidney(15)(15)(15)(15)(15)(15)
 Hydronephrosis1 (7%)
 Infarct1 (7%)2 (13%)
 Infiltration cellular2 (13%)3 (20%)
 Inflammation, chronic active1 (7%)4 (27%)4 (27%)3 (20%)
 Mineralization1 (7%)
 Myelodysplasia4 (27%)
 Nephropathy6 (40%)1 (7%)
 Pigmentation1 (7%)
 Cortex, cyst1 (7%)1 (7%)1 (7%)1 (7%)
 Renal tubule, dilatation1 (7%)
 Renal tubule, regeneration1 (7%)2 (13%)3 (20%)
a

Number of animals examined microscopically at the site and the number of animals with lesion

From: APPENDIX A, SUMMARY OF LESIONS IN MALE Tg.AC HEMIZYGOUS MICE IN THE 6-MONTH DERMAL STUDY OF PENTAERYTHRITOL TRIACRYLATE

Cover of NTP Genetically Modified Model Report on the Toxicology Studies of Pentaerythritol Triacrylate (Technical Grade) (CASRN 3524-68-3) in F344/N Rats, B6C3F1 Mice, and Genetically Modified (FVB Tg.AC Hemizygous) Mice (Dermal Studies)
NTP Genetically Modified Model Report on the Toxicology Studies of Pentaerythritol Triacrylate (Technical Grade) (CASRN 3524-68-3) in F344/N Rats, B6C3F1 Mice, and Genetically Modified (FVB Tg.AC Hemizygous) Mice (Dermal Studies): NTP GMM 04 [Internet].
Chhabra RS, Mahler J, Bristol DW, et al.
Research Triangle Park (NC): National Toxicology Program; 2005 Oct.
Copyright Notice

This is a work of the US government and distributed under the terms of the Public Domain

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.